PRTK Paratek Pharmaceuticals Inc.

5.57
0  0%
Previous Close 5.57
Open 5.64
Price To Book 3.79
Market Cap 180556992
Shares 32,415,977
Volume 338,221
Short Ratio
Av. Daily Volume 289,854

NewsSee all news

  1. Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations
  2. Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  3. Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019
  4. Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award
  5. Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved November 23, 2011.
Intermezzo
Insomnia
Phase 3 data released July 17, 2017 - all endpoints met.
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Omadacycline
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Omadacycline
Community-acquired bacterial pneumonia (CABP)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
Phase 2 data due 2H 2019.
Omadacycline
Urinary tract infections
Phase 2 dosing announced November 27, 2018 with data due 2H 2019.
Omadacycline
Complicated urinary tract infections (cUTI) / acute pyelonephritis

Latest News

  1. Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations
  2. Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  3. Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019
  4. Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award
  5. Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings
  6. Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference
  7. Seth Klarman's Small Caps: Worth a Look?
  8. Paratek Pharmaceuticals Announces Management Change
  9. What Should Investors Know About Paratek Pharmaceuticals, Inc.’s (NASDAQ:PRTK) Future?
  10. Edited Transcript of PRTK earnings conference call or presentation 27-Feb-19 9:30pm GMT
  11. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  12. Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
  13. Paratek Pharmaceuticals Inc (PRTK) Q4 2018 Earnings Conference Call Transcript
  14. Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  15. Will Paratek Pharmaceuticals (PRTK) Report Negative Earnings Next Week? What You Should Know
  16. Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  17. Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019
  18. New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
  19. The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering
  20. Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States